Technical Analysis for BLCM - Bellicum Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 8.49 11.27% 0.86
BLCM closed up 9.63 percent on Friday, May 29, 2020, on 70 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical BLCM trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 11.27%
Wide Bands Range Expansion 11.27%
Wide Bands Range Expansion 21.98%
180 Bullish Setup Bullish Swing Setup 15.20%
Slingshot Bullish Bullish Swing Setup 15.20%
Wide Bands Range Expansion 15.20%
Upper Bollinger Band Walk Strength 16.78%
Wide Bands Range Expansion 16.78%
Upper Bollinger Band Touch Strength 16.78%
Wide Bands Range Expansion 10.12%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of various forms of cancer. Its lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The company is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Its preclinical product candidates include BPX-401, a chimeric antigen receptor (CAR-T) product candidate for the treatment of hematological cancers that express the CD19 antigen; BPX-601, a CAR-T product candidate for treating solid tumors overexpressing the prostate stem cell antigen; and BPX-701, a TCR product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Medicine Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatments Prostate Cancer Virotherapy Vaccination Melanoma Immunotherapies Cell Therapy Transplantation Kite Pharma Hematological Cancers Cancer Vaccine Chimeric Antigen Receptor Treatment Of Hematological Cancers Treatment Of Various Forms Of Cancer

Is BLCM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 27.9
52 Week Low 3.32
Average Volume 124,736
200-Day Moving Average 9.33
50-Day Moving Average 5.61
20-Day Moving Average 6.30
10-Day Moving Average 6.88
Average True Range 0.82
ADX 20.99
+DI 32.28
-DI 14.31
Chandelier Exit (Long, 3 ATRs ) 6.18
Chandelier Exit (Short, 3 ATRs ) 6.84
Upper Bollinger Band 8.23
Lower Bollinger Band 4.37
Percent B (%b) 0.84
BandWidth 61.15
MACD Line 0.43
MACD Signal Line 0.29
MACD Histogram 0.1357
Fundamentals Value
Market Cap 253.51 Million
Num Shares 33.2 Million
EPS -2.94
Price-to-Earnings (P/E) Ratio -2.60
Price-to-Sales 975.18
Price-to-Book 2.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.99
Resistance 3 (R3) 8.92 8.40 8.77
Resistance 2 (R2) 8.40 8.05 8.43 8.69
Resistance 1 (R1) 8.01 7.83 8.20 8.08 8.62
Pivot Point 7.49 7.49 7.58 7.52 7.49
Support 1 (S1) 7.10 7.14 7.30 7.18 6.64
Support 2 (S2) 6.58 6.92 6.61 6.57
Support 3 (S3) 6.19 6.58 6.49
Support 4 (S4) 6.27